Key Takeaways
- • Railpen, a £34bn railways pension scheme and IP Group's largest shareholder with an 18.4% stake, tabled a £581m takeover bid at 69.7p per share (59p cash plus 5p contingent on asset sale), which IP Group rejected as materially undervalued on Tuesday.
- • IP Group's board determined the offer represented a 37% discount to the company's 110.4p net asset value as of 31 December, despite Railpen's positioning of the bid as a solution to the persistent trading discount that has characterized the listed company's performance.
- • Railpen proposed taking IP Group private and establishing a consortium of pension schemes to transform it into a world-class venture capital platform supporting UK science start-ups, while allowing shareholders to retain exposure to IP Group's stake in Oxford Nanopore Technologies.
- • IP Group's rejection followed several months of negotiations, with Railpen having submitted multiple proposals over a two-month period, both rejected on valuation grounds, before eventually withdrawing from pursuit under Rule 2.8 of the City Code on Takeovers and Mergers.
- • The attempted acquisition highlights tension between a pension fund's strategic interest in consolidating venture capital infrastructure around early-stage university spin-offs and public equity holders' valuation expectations for an asset trading at significant discounts to intrinsic value.
Summary
Railpen, the £34bn pension scheme for UK railway workers, made an unsolicited approach to acquire IP Group plc, a £581m early-stage investor specializing in university spin-off companies, in a bid valued at 69.7p per share. The offer comprised 59p in cash with an additional 5p contingent on the sale of one of IP Group's holdings within 12 months. As IP Group's largest shareholder with an 18.4% stake acquired since 2019, Railpen framed the transaction as a strategic consolidation to establish a consortium of pension schemes and create a world-class venture capital platform around IP Group's portfolio of science-focused startups.
IP Group's board rejected the approach on valuation grounds, determining that Railpen's offer represented a 37% discount to the company's 110.4p net asset value as of 31 December 2025. The rejection emphasized that the offer materially undervalued the company, particularly when contextualized against IP Group's recent share price of 70.6p earlier in the month. Railpen's acquisition strategy was positioned as addressing a structural problem that has plagued IP Group as a public company: a persistent and significant discount to net asset value, which the pension fund attributed to the challenging experience of operating as a listed entity.
The failed takeover approach reflected several months of negotiation between the parties, with Railpen tabling multiple proposals over a two-month window, all rejected on valuation grounds. Railpen's consolidation strategy held appeal for long-term institutional capital: the pension fund explicitly committed to reinvesting the company's full earnings and maintaining shareholder exposure to IP Group's position in Oxford Nanopore Technologies, a high-profile gene sequencing company in the portfolio. However, the valuation disconnect between Railpen's bid and IP Group's asset-backed valuation proved insurmountable. Following the rejection, Railpen withdrew from pursuit of the transaction and became subject to Rule 2.8 restrictions under the City Code on Takeovers and Mergers, preventing renewed approach attempts within a defined period.
IP Group's board rejected the approach on valuation grounds, determining that Railpen's offer represented a 37% discount to the company's 110.4p net asset value as of 31 December 2025. The rejection emphasized that the offer materially undervalued the company, particularly when contextualized against IP Group's recent share price of 70.6p earlier in the month. Railpen's acquisition strategy was positioned as addressing a structural problem that has plagued IP Group as a public company: a persistent and significant discount to net asset value, which the pension fund attributed to the challenging experience of operating as a listed entity.
The failed takeover approach reflected several months of negotiation between the parties, with Railpen tabling multiple proposals over a two-month window, all rejected on valuation grounds. Railpen's consolidation strategy held appeal for long-term institutional capital: the pension fund explicitly committed to reinvesting the company's full earnings and maintaining shareholder exposure to IP Group's position in Oxford Nanopore Technologies, a high-profile gene sequencing company in the portfolio. However, the valuation disconnect between Railpen's bid and IP Group's asset-backed valuation proved insurmountable. Following the rejection, Railpen withdrew from pursuit of the transaction and became subject to Rule 2.8 restrictions under the City Code on Takeovers and Mergers, preventing renewed approach attempts within a defined period.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.